http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109982701-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4725 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4725 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-04 |
| filingDate | 2018-06-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-04-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-04-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-109982701-B |
| titleOfInvention | Use of SERD and CDK4/6 inhibitors and PI3K/mTOR pathway inhibitors |
| abstract | Provided is the use of a SERD and CDK4/6 inhibitor and a PI3K/mTOR pathway inhibitor. Specifically, a selective estrogen receptor downregulator (SERD) and a cyclin-dependent kinase 4/6 inhibitor (CDK4/6), a phosphatidylinositol 3-kinase (PI3K)/ Use of one or more combinations of target of rapamycin (mTOR) pathway inhibitors in the preparation of a medicament for treating breast tumors. |
| priorityDate | 2017-06-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 340.